Hypoxia potentiates the capacity of melanoma cells to evade cisplatin and doxorubicin cytotoxicity via glycolytic shift.

FEBS Open Bio
Ming ZhuoElla W Englander

Abstract

The hypoxic environment within solid tumors impedes the efficacy of chemotherapeutic treatments. Here, we demonstrate that hypoxia augments the capacity of melanoma cells to withstand cisplatin and doxorubicin cytotoxicity. We show that B16F10 cells derived from spontaneously formed melanoma and YUMM1.7 cells, engineered to recapitulate human-relevant melanoma driver mutations, profoundly differ in their vulnerabilities to cisplatin and doxorubicin. The differences are manifested in magnitude of proliferative arrest and cell death rates, extent of mtDNA depletion, and impairment of mitochondrial respiration. In both models, cytotoxicity is mitigated by hypoxia, which augments glycolytic metabolism. Collectively, the findings implicate metabolic reprogramming in drug evasion and suggest that melanoma tumors with distinct genetic makeup may have differential drug vulnerabilities, highlighting the importance of precision anticancer treatments.

References

Jul 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·D A ClaytonE C Friedberg
Sep 16, 1999·Mutation Research·D L CroteauV A Bohr
Jan 27, 2004·Oncogene·Vladislava O MelnikovaHonnavara N Ananthaswamy
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Jun 27, 2009·Analytical Chemistry·Akos A GerencserMartin D Brand
May 8, 2010·Clinical Chemistry·David DimmockLee-Jun C Wong
Jun 11, 2010·Chemistry & Biology·Yves PommierChristophe Marchand
Dec 15, 2010·Neurobiology of Disease·Jewel L PodratzAnthony J Windebank
Jan 15, 2011·Current Protocols in Human Genetics·Victor VenegasLee-Jun Wong
Jul 6, 2011·The Biochemical Journal·Martin D Brand, David G Nicholls
Aug 17, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Inna SerganovaJason A Koutcher
Aug 30, 2011·Free Radical Biology & Medicine·Brian P DrankaVictor M Darley-Usmar
Aug 11, 2012·Advances in Experimental Medicine and Biology·A A ShestovJ D Glickson
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Salim KhiatiYves Pommier
May 23, 2015·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Helena DoktorovaTomas Eckschlager
Oct 21, 2015·Molecular Cell·Emily D MontalGeoffrey D Girnun
Jun 9, 2016·Oncogene·B I RatnikovZ A Ronai
Jun 12, 2016·Pigment Cell & Melanoma Research·Katrina MeethMarcus W Bosenberg
Oct 21, 2016·Nature Reviews. Molecular Cell Biology·Yves PommierJohn L Nitiss
Jun 13, 2018·The FEBS Journal·Pierre-Benoit AnceyEtienne Meylan
Aug 18, 2018·Pigment Cell & Melanoma Research·Janine RegneriManfred Schartl
Oct 17, 2018·International Journal of Nanomedicine·Kaitlin Graham, Evan Unger
Jan 23, 2019·Critical Reviews in Biochemistry and Molecular Biology·Shanmugasundaram Ganapathy-Kanniappan
Feb 1, 2019·Pigment Cell & Melanoma Research·Kim R M BlenmanMarcus Bosenberg
Apr 20, 2019·Pigment Cell & Melanoma Research·Christopher LiDouglas Grossman
Sep 5, 2019·Cell Metabolism·Jiyeon Kim, Ralph J DeBerardinis
Oct 11, 2019·Science Translational Medicine·Salo N OoftEmile E Voest

❮ Previous
Next ❯

Software Mentioned

imagej
GraphPad
prism
qcapture pro ( QImaging )
[UNK]

Related Concepts

Related Feeds

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.